Jean Hu-Primmer is currently the Sr Advisor for CBRN and Pandemic Influenza in the Food and Drug Administration (FDA) Office of Counterterrorism and Emerging Threats (OCET). Jean has extensive experience within the Department of Health and Human Services. Her FDA achievements include the development, implementation and management of OCET’s Medical Countermeasures (MCM) Initiative Regulatory Science Program, which fosters science and technology projects that facilitate FDA review of MCMs against CBRN and emerging disease threats.
Prior to OCET, Jean was a health scientist in the Influenza Division at the Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response (ASPR), where she served as the program champion for BARDA’s universal influenza vaccine program, providing subject matter expertise in product and clinical development, as well as BARDA’s continuous manufacturing program, a joint initiative with FDA’s Emerging Technologies Team. During the early years of her tenure with the federal government, Jean worked as a research scientist both at FDA’s Center for Biologics Evaluation and Research (CBER) and the Centers for Disease Control and Prevention (CDC) in the area of influenza vaccine development, immunology and viral pathogenesis, including highly pathogenic avian influenza A/H5N1. Jean also spent time in her federal career in regulatory affairs for the National Institutes of Allergy and Infectious Diseases, Division of Microbiology and Infectious Diseases where her responsibility included management of the entire extramural influenza vaccine clinical trials regulatory portfolio for the Division.
Jean holds a BS in microbiology from Cornell University and a MS in cellular/molecular biology from the University of West Florida, completing a thesis defense for the enhancement of the aromatic chlorinated hydrocarbon degradation using a cloned hemoglobin gene in Burkholderia cepacia.